Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rang in Aktien #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aktienkurs
$0.30780727
Marktkapitalisierung
$94.19M
Veränderung (1 Tag)
-0.19%
Veränderung (1 Jahr)
-34.73%
Land
FR
Handel Sensorion SA (ALSEN)

Kategorie

Dividendenrendite-Verlauf für Sensorion SA (ALSEN)
Dividendenrendite (TTM) von Sensorion SA (Aktienkürzel: ALSEN) zum 2023-12-31: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Sensorion SA (ALSEN) von 2011 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber